Showing results (541-550 of 3,788) with videos related to
Sort By:
Pageof 379
Oncoimmunology|May 4, 2016
PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunityTong Seng Lim, Valerie Chew, Je Lin Sieow, et al.Oncoimmunology|May 4, 2016
The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancersFrançois Bertucci, Pascal Finetti, Daniel Birnbaum, et al.Oncoimmunology|May 4, 2016
Targeted immunotherapy for pediatric solid tumorsLisa M Kopp, Emmanuel KatsanisOncoimmunology|May 4, 2016
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse modelDe-Kuan Chang, Eric Peterson, Jiusong Sun, et al.Oncoimmunology|May 4, 2016
Pharmacological DNA demethylation: Implications for cancer immunotherapyDavid Roulois, Helen Loo Yau, Daniel D De CarvalhoOncoimmunology|May 4, 2016
Tumor-induced neutrophil extracellular traps-drivers of systemic inflammation and vascular dysfunctionJessica Cedervall, Anna Dimberg, Anna-Karin OlssonOncoimmunology|May 4, 2016
IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?Jakub Tomala, Marek KovarOncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.Oncoimmunology|May 4, 2016
Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transferGuy Berchem, Muhammad Zaeem Noman, Manon Bosseler, et al.Oncoimmunology|May 4, 2016
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLCBenjamin Besse, Mélinda Charrier, Valérie Lapierre, et al.Pageof 379